PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and CureVac (NASDAQ:CVAC – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.
Institutional and Insider Ownership
17.3% of CureVac shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by company insiders. Comparatively, 2.2% of CureVac shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares PTC Therapeutics and CureVac”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PTC Therapeutics | $806.78 million | 7.58 | -$363.30 million | $8.56 | 8.90 |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
CureVac has lower revenue, but higher earnings than PTC Therapeutics. CureVac is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares PTC Therapeutics and CureVac’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PTC Therapeutics | 42.25% | -194.11% | 33.15% |
| CureVac | 199.92% | -23.03% | -19.09% |
Analyst Ratings
This is a summary of current ratings and price targets for PTC Therapeutics and CureVac, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PTC Therapeutics | 1 | 6 | 9 | 0 | 2.50 |
| CureVac | 1 | 4 | 1 | 0 | 2.00 |
PTC Therapeutics currently has a consensus target price of $77.27, suggesting a potential upside of 1.44%. CureVac has a consensus target price of $6.83, suggesting a potential upside of 46.64%. Given CureVac’s higher probable upside, analysts clearly believe CureVac is more favorable than PTC Therapeutics.
Risk and Volatility
PTC Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
